FCAAIA Notes: Sublingual immunotherapy (SLIT) tablets are already FDA approved for grass and ragweed. Personally, I have not found that they have a great role in the care of patients here in southwestern Connecticut. There are few patients so allergic to only those allergens that they require immunotherapy. If patients are on injections (subcutaneous allergen immunotherapy, SCIT) for multiple allergens, grass and ragweed are included if indicated. The tablets are very expensive and often not covered by insurance.
However, there are more patients allergic only to dust mites who are bad enough that immunotherapy is indicated. SLIT tablets are an alternative for those patients when they reach the market.
A great weakness in the study and marketing of new products is that they are usually not compared to existing products in head-to-head studies. Continue reading “ODACTRA FIRST SUBLINGUAL THERAPY OK’D FOR HO– USE DUST MITE ALLERGY”
FCAAIA Notes: The vast majority of children with asthma have allergies and should have allergy testing. Therefore, a thorough history of environmental exposures, correlated with the patient’s history and his testing results allow for focused recommendations for allergen avoidance.
The role of allergy in asthma is so well established that national and international guidelines for the care of asthma indicate that patients with persistent asthma (and allergy) should be considered candidates for allergy shots. Continue reading “AAP: INDOOR ALLERGEN TESTING ‘A MUST’ FOR KIDS WITH ASTHMA”
FCAAIA Notes: I have posted many articles about sublingual immunotherapy (SLIT, under-the –tongue) on our web site. Only grass and ragweed tablets are currently licensed in the United States. All other forms of SLIT in the US are not FDA approved and are “off-label”.
In general, allergy shots are at least as or more effective than SLIT. In this study, dust mite SLIT was compared to placebo, but not to dust mite shots. Continue reading “DUST MITE SLIT PROMISING ADD-ON TO ASTHMA MAINTENANCE MEDS”